Galena Biopharma (GALE) Earning Somewhat Positive Press Coverage, Accern Reports
Media headlines about Galena Biopharma (NASDAQ:GALE) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galena Biopharma earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.7564023392383 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Honing in on Shares of Galena Biopharma, Inc. (NASDAQ:GALE) – FLBC News (flbcnews.com)
- Traders Recap – Cabot Oil & Gas Corporation (NYSE:COG), Galena Biopharma Inc (NASDAQ:GALE) – Stock Watch (stocksnewstimes.com)
- Stock Moving Towards 52-Week Low Galena Biopharma, Inc. (NASDAQ:GALE) – Sparta Review (spartareview.com)
- Is Now the Time to Capitalize on Galena Biopharma, Inc. (NASDAQ:GALE) Shares? – FLBC News (flbcnews.com)
- Galena Biopharma Inc (GALE) Share Price Heads Above Balance Step – Financial News Review (finnewsreview.com)
Several equities analysts recently weighed in on the company. ValuEngine cut Galena Biopharma from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research cut Galena Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th.
Galena Biopharma (GALE) traded up 2.4386% during trading on Thursday, reaching $0.5839. The company’s stock had a trading volume of 390,403 shares. The stock’s market cap is $21.86 million. The firm’s 50-day moving average is $0.57 and its 200-day moving average is $0.81. Galena Biopharma has a 52-week low of $0.52 and a 52-week high of $11.18.
Galena Biopharma (NASDAQ:GALE) last announced its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.13. During the same quarter last year, the company earned ($0.07) EPS. Equities research analysts forecast that Galena Biopharma will post ($0.56) EPS for the current year.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.